尼克塔尔治疗股价升, 因为脱发药物显示头发复生. Nektar Therapeutics shares surge after alopecia drug shows hair regrowth.

尼克塔尔治疗公司的股价在宣布其脱发症药物雷斯佩加德莱因研究结果呈阳性后大幅上升. Nektar Therapeutics shares surged after announcing positive results from a study on its alopecia areata drug, rezpegaldesleukin. 治疗显示持续的头发再生,安全性良好,支持进一步发展. The treatment showed continued hair regrowth with a favorable safety profile, supporting further development.